COVID-19 vaccine hesitancy among haemodialysis patients in Burkina Faso: determinants and implications for future strategies
This cross-sectional study of 142 haemodialysis patients in Burkina Faso found a 55.6% prevalence of COVID-19 vaccine hesitancy, identifying fear of vaccination, female gender, and younger age as key determinants, thereby suggesting that future immunization strategies should prioritize communication efforts to address vaccine-related fears.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the world of medicine, some people are more vulnerable to infection than others. Patients with failing kidneys who rely on a machine to filter their blood, a treatment known as haemodialysis, face a particularly high risk. Their bodies struggle to fight off germs because the disease that damaged their kidneys also weakens their immune system, and the treatment itself can accelerate the natural aging of their immune defenses. For these individuals, vaccination is not just a precaution; it is a critical shield against severe illness and death. Yet, even when vaccines are available and offered freely, many people hesitate to take them. This reluctance, a complex mix of fear, doubt, and hesitation, can derail public health efforts. Understanding why this happens is essential, especially in regions where data is scarce and healthcare systems face unique challenges.
In Burkina Faso, a team of researchers set out to understand this hesitation among the country's haemodialysis patients. They conducted a survey at the main hospital in the capital, interviewing patients over a single week in July 2021. This was a time when the national vaccination campaign had just begun, and people with kidney failure had been identified as a priority group to receive the shots. The researchers spoke directly with 142 patients, asking them about their willingness to be vaccinated, their fears regarding the disease, and their feelings about the vaccine itself. They wanted to know not just how many people were hesitant, but what specific factors were driving that hesitation.
The results painted a clear picture of a population caught between the need for protection and the fear of the solution. More than half of the patients surveyed, specifically 55.6 percent, expressed hesitation about receiving the COVID-19 vaccine. This means that out of every two patients, one was unsure or unwilling to get vaccinated despite being in a high-risk group. The study revealed that this hesitation was not random; it was strongly linked to three main factors. First, being a woman made a patient nearly three times more likely to be hesitant than a man. Second, patients under the age of 60 were more than four times more likely to hesitate compared to their older counterparts. Finally, and perhaps most significantly, a specific fear of the vaccine itself was the strongest predictor. Patients who were afraid of the injection or its potential side effects were almost five times more likely to refuse the vaccine.
What makes these findings particularly important is what they ruled out. The researchers found that simply knowing the disease was dangerous was not enough to change minds. Many patients understood that kidney failure made them more likely to suffer severe outcomes from COVID-19, and many were even afraid of the virus itself. Yet, this fear of the disease did not translate into a willingness to get vaccinated. This suggests that the barrier to vaccination was not a lack of knowledge about the threat, but rather a deep-seated anxiety about the vaccine. The study also found that patients who had previously been vaccinated were significantly less likely to be hesitant about the COVID-19 vaccine, indicating that prior positive experiences with immunization can build trust, though each campaign still requires specific approaches to maintain that confidence.
The researchers concluded that future efforts to protect this vulnerable group must change their strategy. Simply telling patients how dangerous the virus is, or how many people are dying, is insufficient if the patients are terrified of the needle. Instead, the most effective path forward involves addressing the fear of the vaccine directly. This means healthcare teams, particularly the doctors and nurses who see these patients twice a week during their dialysis sessions, need to engage in open, reassuring conversations. They must be ready to discuss safety, explain how the vaccines work, and be transparent about potential side effects. By focusing on alleviating the specific fear of the injection rather than just highlighting the severity of the disease, healthcare providers can build the trust necessary to save lives. The study suggests that when the people who care for these patients daily become the primary messengers of reassurance, the hesitation may finally begin to fade.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.